kolnauhc (@kolnauhc) profile picture

show me the incentive and I show you the outcome.

Singapore
Joined March 2009
Photo by kolnauhc (@kolnauhc)Photo by kolnauhc (@kolnauhc)Photo by kolnauhc (@kolnauhc)Photo by kolnauhc (@kolnauhc)Photo by kolnauhc (@kolnauhc)Photo by kolnauhc (@kolnauhc)Photo by kolnauhc (@kolnauhc)Photo by kolnauhc (@kolnauhc)Photo by kolnauhc (@kolnauhc)Photo by kolnauhc (@kolnauhc)
My competitive edge is reading up histories of folks who post smart stuff on twitter and trying to copy their portfolio. Bizarre.
9
kolnauhc retweeted
Lmao
1
1
15
1,074
First favus then scorpion. Pft.
34
Funny how the previous hotel had a sanofi event and now astra zeneca. Maybe it’s a sign of who is buying $abvx
3
632
Nice update in the $abvx deck again. Anyone has any summary or recordings of what’s shared in the LifeSci Capital X event?
1
477
kolnauhc retweeted
Carlsen's Queen Sacrifice Wins the World Title | Carlsen vs Karjakin, World Championship 2016
6
22
2
202
18,488
Thinking of Combo studies design
1
69
Ease to prescribe based on label and prechecks required
9
Listening to $sny call, makes me hoping as a bag holder of $abvx that they overpay lol.
1
3
1,359
When Crohn’s readout is positive and shows best in disease, will they become too expensive to be purchased? Or still single digit MC….
3rd and final earnings observation of the day, this time relating to $ABVX. UCB and Galderma are both European SMID biopharmas that are ABSOLUTELY CRUSHING IT launching into competitive I&I indications ON THEIR OWN. UCB, located in Belgium, launched Bimzelx into psoriasis and HS. Galderma, located in Switzerland, launched Nemluvio into atopic dermatitis and prurigo nodularis. Both European. Both independent launches. Both late-comers to large I&I indications with multiple competitive drug approvals already there. Both absolutely rocketing throughout their solo launches. *BOTH* of these companies have nearly tripled their market caps (both over $40B now) since the launch of their flagship I&I drugs. TRIPLED! Sure they have other assets, but it's obviously Nemluvio and bimzelx that are driving their valuations/growth. These stories are incredibly analogous to $ABVX, aside from the fact that Obefazimod would be the only one in this group that has the obviously best-in-disease asset. Why would we have any doubt that a GIA launch here would be any different, if not *better*? The "go it alone" UC-only case for $ABVX sets the floor for its valuation. In my strong opinion, we are currently trading beneath that floor as is. The "short the launch" mantra for SMID bios is dead. The market hasn't totally accepted that yet, but it is clearly evident if you're paying attention. We've got Belgian/Swiss biotechs going up against Dupixent, Humira, Cosentyx, Ebglyss, Rinvoq ($SNY $REGN $NVS $LLY $ABBV) etc etc etc and still absolutely crushing it. *Crushing* it. If you're looking at the GIA case for $ABVX as a negative scenario from the current price, I don't think you're paying any attention at all. That doesn't mean I think they won't be bought. I still think that is highly likely. But the floor here is being incredibly misjudged, and we have an abundance of real world evidence to support this.
90
kolnauhc retweeted
$ABVX I was doing some Chat research and discovered that $ABVX published a new patent application in August 2026. Anyone talk about this yet? They are attempting to cover specific dosing schedules (25 mg and 50 mg) in maintenance treatment. Chat tells me that, if granted, the patent could provide protection through 2044. Chat also told me that competitors/generics could design around the dosing claims and gave a bunch of other caveats - it's far from a done deal. I have very little knowledge of patent law and this could just be abivax throwing things against the wall and seeing what sticks. Apparently, Abbvie has a similar dosing patent for Rinvoq (45mg induction then 15mg maintenance) that was granted. Anyone who knows more than me able to opine? patents.google.com/patent/US…
2
26
2,408
Buyout Monday guaranteed.
🤖 Made with AI
1
88
$sln done. Now where’s my $ABVX
1
335
kolnauhc retweeted
Daphne rn
FWIW hearing from M&A focused banks that there are multiple deals in the works and sounds like a couple of substantial ones could get announced in the near term (weeks). Will hopefully help with sentiment for biotech $XBI $BBC
4
4
147
14,021
Was thinking through the quote on best in disease results. Would be interesting to see how the doctors interpret the results and the patients well being. The thought was that this could become a winner take all disease. 20% market share expectation seems very low comparatively.
Replying to @bioinvestor24
Endoscopic remission and HEMI are the main drivers. Even Lily was forced to release those data today. The field has evolved in last 5-10 years from symptom hiding to fixing core disease. It is not possible for any combo to beat those parameters unless one of the drug in combo is Obe itself. You didn’t answer my question other day how 8-9% ER combo drugs will beat 38%. Obe USP is not that it’s oral but it’s what it does. Convenience of dosing or long acting agents may only work in non-serious or non-life threatening diseases where there is no urgency for right treatment. Imagine if I tell you cancer patients should take long acting 6 months OS Biologics instead of daily Daraxonrasib pill with 13.2 months OS. Sounds ridiculous, right? Or, patients should take only pain killers and not fix the actual injury causing the pain? Only masking symptoms in IBD comes with very heavy price later in life. For some as quickly as 30 days. How can you praise Tremfya uptake and in the same tweet be hesitant about Obe uptake (using well clarified cancer scare) when Tremfya has history of highest malignancies in phase 3 (even more than Obe)? That drugs is being sold with clean label for 10 years now. I wrote in detail last week if you are interested. Do you also know that Icotyde reported one malignancy in phase 2 which obe also reported one in much larger and longer phase 2? I don’t know about BO but one guess if I have to make I would say Merck who is on its way to release disaster Tuli IBD maintenance data. $ABVX
1
131
Why use less efficacious drugs in 1L and keep the more efficacious drug in 2L? Insurance/payors preference? The QoL discussion should drive a lot of good conversations.
1
67